Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein.

Belliotti TR, Capiris T, Ekhato IV, Kinsora JJ, Field MJ, Heffner TG, Meltzer LT, Schwarz JB, Taylor CP, Thorpe AJ, Vartanian MG, Wise LD, Zhi-Su T, Weber ML, Wustrow DJ.

J Med Chem. 2005 Apr 7;48(7):2294-307.

PMID:
15801823
2.

Orally active analogues of the dopaminergic prodrug 6-(N,N-di-n-propylamino)-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one: synthesis and pharmacological activity.

Venhuis BJ, Dijkstra D, Wustrow DJ, Meltzer LT, Wise LD, Johnson SJ, Heffner TG, Wikström HV.

J Med Chem. 2003 Feb 13;46(4):584-90.

PMID:
12570379
3.

The discovery of PD 89211 and related compounds: selective dopamine D4 receptor antagonists.

Pugsley TA, Shih YH, Whetzel SZ, Zoski K, Van Leeuwen D, Akunne H, Mackenzie R, Heffner TG, Wustrow D, Wise LD.

Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):219-26.

PMID:
11817497
4.

Thiazoloindans and thiazolobenzopyrans: a novel class of orally active central dopamine (partial) agonists.

van Vliet LA, Rodenhuis N, Wikström H, Pugsley TA, Serpa KA, Meltzer LT, Heffner TG, Wise LD, Lajiness ME, Huff RM, Svensson K, Haenen GR, Bast A.

J Med Chem. 2000 Sep 21;43(19):3549-57.

PMID:
11000009
5.

Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).

van Vliet LA, Rodenhuis N, Dijkstra D, Wikström H, Pugsley TA, Serpa KA, Meltzer LT, Heffner TG, Wise LD, Lajiness ME, Huff RM, Svensson K, Sundell S, Lundmark M.

J Med Chem. 2000 Jul 27;43(15):2871-82.

PMID:
10956195
6.

PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.

Corbin AE, Meltzer LT, Ninteman FW, Wiley JN, Christoffersen CL, Wustrow DJ, Wise LD, Pugsley TA, Heffner TG.

Neuropharmacology. 2000 Apr 27;39(7):1211-21.

PMID:
10760363
7.

PD 158771, a potential antipsychotic agent with D(2)/D(3) partial agonist and 5-HT(1A) agonist actions. I. Neurochemical effects.

Akunne HC, Zoski KT, Davis MD, Cooke LW, Meltzer LT, Whetzel SZ, Shih YH, Wustrow DJ, Wise LD, MacKenzie RG, Georgic LM, Heffner TG, Pugsley TA.

Neuropharmacology. 2000 Apr 27;39(7):1197-210.

PMID:
10760362
8.

A series of 6- and 7-piperazinyl- and -piperidinylmethylbenzoxazinones with dopamine D4 antagonist activity: discovery of a potential atypical antipsychotic agent.

Belliotti TR, Wustrow DJ, Brink WA, Zoski KT, Shih YH, Whetzel SZ, Georgic LM, Corbin AE, Akunne HC, Heffner TG, Pugsley TA, Wise LD.

J Med Chem. 1999 Dec 16;42(25):5181-7.

PMID:
10602703
9.

Design, synthesis, and evaluation of chromen-2-ones as potent and selective human dopamine D4 antagonists.

Kesten SR, Heffner TG, Johnson SJ, Pugsley TA, Wright JL, Wise LD.

J Med Chem. 1999 Sep 9;42(18):3718-25.

PMID:
10479303
10.

Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists.

Wustrow DJ, Capiris T, Rubin R, Knobelsdorf JA, Akunne H, Davis MD, MacKenzie R, Pugsley TA, Zoski KT, Heffner TG, Wise LD.

Bioorg Med Chem Lett. 1998 Aug 18;8(16):2067-70.

PMID:
9873487
11.

Isoindolinone enantiomers having affinity for the dopamine D4 receptor.

Belliotti TR, Brink WA, Kesten SR, Rubin JR, Wustrow DJ, Zoski KT, Whetzel SZ, Corbin AE, Pugsley TA, Heffner TG, Wise LD.

Bioorg Med Chem Lett. 1998 Jun 16;8(12):1499-502.

PMID:
9873377
12.

Pharmacological characterization of PD 152255, a novel dimeric benzimidazole dopamine D3 antagonist.

Corbin AE, Pugsley TA, Akunne HC, Whetzel SZ, Zoski KT, Georgic LM, Nelson CB, Wright JL, Wise LD, Heffner TG.

Pharmacol Biochem Behav. 1998 Feb;59(2):487-93.

PMID:
9476999
13.

(Aryloxy)alkylamines as selective human dopamine D4 receptor antagonists: potential antipsychotic agents.

Unangst PC, Capiris T, Connor DT, Doubleday R, Heffner TG, MacKenzie RG, Miller SR, Pugsley TA, Wise LD.

J Med Chem. 1997 Dec 5;40(25):4026-9.

PMID:
9406594
14.

Chromeno[3,4-c]pyridin-5-ones: selective human dopamine D4 receptor antagonists as potential antipsychotic agents.

Unangst PC, Capiris T, Connor DT, Heffner TG, MacKenzie RG, Miller SR, Pugsley TA, Wise LD.

J Med Chem. 1997 Aug 15;40(17):2688-93.

PMID:
9276014
15.

Substituted [(4-phenylpiperazinyl)-methyl]benzamides: selective dopamine D4 agonists.

Glase SA, Akunne HC, Georgic LM, Heffner TG, MacKenzie RG, Manley PJ, Pugsley TA, Wise LD.

J Med Chem. 1997 Jun 6;40(12):1771-2. No abstract available.

PMID:
9191952
16.

Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys.

Feng MR, Corbin AE, Wang Y, Christoffersen CL, Wiley JN, Strenkoski CA, Tucker EV, Ninteman FW, Meltzer LT, Heffner TG, Wright DS.

Pharm Res. 1997 Mar;14(3):329-36.

PMID:
9098876
18.

3-[[(4-Aryl-1-piperazinyl)alkyl]cyclohexyl]-1H-indoles as dopamine D2 partial agonists and autoreceptor agonists.

Wustrow DJ, Smith WJ 3rd, Corbin AE, Davis MD, Georgic LM, Pugsley TA, Whetzel SZ, Heffner TG, Wise LD.

J Med Chem. 1997 Jan 17;40(2):250-9.

PMID:
9003524
19.

The pharmacology of the novel and selective sigma ligand, PD 144418.

Akunne HC, Whetzel SZ, Wiley JN, Corbin AE, Ninteman FW, Tecle H, Pei Y, Pugsley TA, Heffner TG.

Neuropharmacology. 1997 Jan;36(1):51-62.

PMID:
9144641
20.

Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity.

van Vliet LA, Tepper PG, Dijkstra D, Damsma G, Wikström H, Pugsley TA, Akunne HC, Heffner TG, Glase SA, Wise LD.

J Med Chem. 1996 Oct 11;39(21):4233-7.

PMID:
8863800
21.

Aryl 1-but-3-ynyl-4-phenyl-1,2,3,6-tetrahydropyridines as potential antipsychotic agents: synthesis and structure-activity relationships.

Glase SA, Akunne HC, Heffner TG, Jaen JC, MacKenzie RG, Meltzer LT, Pugsley TA, Smith SJ, Wise LD.

J Med Chem. 1996 Aug 2;39(16):3179-87.

PMID:
8759640
22.
23.

Synthesis and dopaminergic activity of pyridine analogs of 5-hydroxy-2-(di-n-propylamino)tetralin.

Glase SA, Corbin AE, Pugsley TA, Heffner TG, Wise LD.

J Med Chem. 1995 Aug 4;38(16):3132-7.

PMID:
7636875
24.

CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.

Meltzer LT, Christoffersen CL, Corbin AE, Ninteman FW, Serpa KA, Wiley JN, Wise LD, Heffner TG.

J Pharmacol Exp Ther. 1995 Aug;274(2):912-20.

PMID:
7636754
25.

Agonist properties of a stable hexapeptide analog of neurotensin, N alpha MeArg-Lys-Pro-Trp-tLeu-Leu (NT1).

Akunne HC, Demattos SB, Whetzel SZ, Wustrow DJ, Davis DM, Wise LD, Cody WL, Pugsley TA, Heffner TG.

Biochem Pharmacol. 1995 Apr 18;49(8):1147-54.

PMID:
7748196
26.

Differential effects of the nonpeptide neurotensin antagonist, SR 48692, on the pharmacological effects of neurotensin agonists.

Pugsley TA, Akunne HC, Whetzel SZ, Demattos S, Corbin AE, Wiley JN, Wustrow DJ, Wise LD, Heffner TG.

Peptides. 1995;16(1):37-44.

PMID:
7716073
27.

Characterization of binding of [3H]PD 128907, a selective dopamine D3 receptor agonist ligand, to CHO-K1 cells.

Akunne HC, Towers P, Ellis GJ, Dijkstra D, Wikström H, Heffner TG, Wise LD, Pugsley TA.

Life Sci. 1995;57(15):1401-10.

PMID:
7674830
28.

Studies of the active conformation of a novel series of benzamide dopamine D2 agonists.

Wustrow DJ, Wise LD, Cody DM, MacKenzie RG, Georgic LM, Pugsley TA, Heffner TG.

J Med Chem. 1994 Nov 25;37(24):4251-7.

PMID:
7990124
29.

The discovery and structure-activity relationships of 1,2,3,6-tetrahydro-4-phenyl-1-[(arylcyclohexenyl)alkyl]pyridines. Dopamine autoreceptor agonists and potential antipsychotic agents.

Wright JL, Caprathe BW, Downing DM, Glase SA, Heffner TG, Jaen JC, Johnson SJ, Kesten SR, MacKenzie RG, Meltzer LT, et al.

J Med Chem. 1994 Oct 14;37(21):3523-33.

PMID:
7932581
30.

Structure-activity and conformational studies of a series of modified C-terminal hexapeptide neurotensin analogues.

Heyl DL, Sefler AM, He JX, Sawyer TK, Wustrow DJ, Akunne HC, Davis MD, Pugsley TA, Heffner TG, Corbin AE, et al.

Int J Pept Protein Res. 1994 Sep;44(3):233-8.

PMID:
7822099
31.

Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand.

Damsma G, Bottema T, Westerink BH, Tepper PG, Dijkstra D, Pugsley TA, MacKenzie RG, Heffner TG, Wikström H.

Eur J Pharmacol. 1993 Nov 16;249(3):R9-10.

PMID:
8287911
32.

Effects of caffeine and PD 116,600 on the differential-reinforcement-of-low rate 72-S (DRL 72-S) schedule of reinforcement.

Marek GJ, Heffner TG, Richards JB, Shaughnessy RA, Li AA, Seiden LS.

Pharmacol Biochem Behav. 1993 Aug;45(4):987-90.

PMID:
8415842
33.

Lack of involvement of haloperidol-sensitive sigma binding sites in modulation of dopamine neuronal activity and induction of dystonias by antipsychotic drugs.

Meltzer LT, Christoffersen CL, Serpa KA, Pugsley TA, Razmpour A, Heffner TG.

Neuropharmacology. 1992 Sep;31(9):961-7.

PMID:
1359446
34.

Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents.

Sebolt-Leopold JS, Vincent PW, Beningo KA, Elliott WL, Leopold WR, Heffner TG, Wiley JN, Stier MA, Suto MJ.

Int J Radiat Oncol Biol Phys. 1992;22(3):549-51.

PMID:
1531213
35.

Effects of CI-943, a potential antipsychotic drug, and haloperidol on regional brain neurotensin concentrations.

Levant B, Bissette G, Davis MD, Heffner TG, Nemeroff CB.

Synapse. 1991 Nov;9(3):225-30.

PMID:
1685600
36.

Dopamine autoreceptor agonists as potential antipsychotics. 3.6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.

Caprathe BW, Jaen JC, Wise LD, Heffner TG, Pugsley TA, Meltzer LT, Parvez M.

J Med Chem. 1991 Sep;34(9):2736-46.

PMID:
1680195
37.

Dopamine autoreceptor agonists as potential antipsychotics. 2. (Aminoalkoxy)-4H-1-benzopyran-4-ones.

Jaen JC, Wise LD, Heffner TG, Pugsley TA, Meltzer LT.

J Med Chem. 1991 Jan;34(1):248-56.

PMID:
1671416
38.

Synthesis and dopamine agonist properties of (+-)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers.

DeWald HA, Heffner TG, Jaen JC, Lustgarten DM, McPhail AT, Meltzer LT, Pugsley TA, Wise LD.

J Med Chem. 1990 Jan;33(1):445-50.

PMID:
1967318
39.

4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties.

Jaen JC, Wise LD, Caprathe BW, Tecle H, Bergmeier S, Humblet CC, Heffner TG, Meltzer LT, Pugsley TA.

J Med Chem. 1990 Jan;33(1):311-7.

PMID:
1967314
40.
41.

CI-943, a potential antipsychotic agent. III. Evaluation of effects on dopamine neuronal activity.

Meltzer LT, Christoffersen CL, Heffner TG, Freeman AS, Chiodo LA.

J Pharmacol Exp Ther. 1989 Oct;251(1):123-30.

PMID:
2571714
42.

CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.

Heffner TG, Downs DA, Meltzer LT, Wiley JN, Williams AE.

J Pharmacol Exp Ther. 1989 Oct;251(1):105-12.

PMID:
2571712
43.

Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice.

Heffner TG, Wiley JN, Williams AE, Bruns RF, Coughenour LL, Downs DA.

Psychopharmacology (Berl). 1989;98(1):31-7.

PMID:
2498959
44.

Dopamine autoreceptor agonists as potential antipsychotics. 1. (Aminoalkoxy)anilines.

Jaen JC, Wise LD, Heffner TG, Pugsley TA, Meltzer LT.

J Med Chem. 1988 Aug;31(8):1621-5.

PMID:
2899647
45.

6- and 8-hydroxy-3,4-dihydro-3-(dipropylamino)-2H-1-benzopyrans. Dopamine agonists with autoreceptor selectivity.

Wise LD, DeWald HA, Hawkins ES, Reynolds DM, Heffner TG, Meltzer LT, Pugsley TA.

J Med Chem. 1988 Mar;31(3):688-91.

PMID:
3346882
46.

Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.

DeWald HA, Beeson NW, Hershenson FM, Wise LD, Downs DA, Heffner TG, Coughenour LL, Pugsley TA.

J Med Chem. 1988 Feb;31(2):454-61.

PMID:
2892936
47.

Evidence for postsynaptic dopamine agonist effects of B-HT 920 in the presence of the dopamine D-1 agonist SKF 38393.

Meltzer LT, Wiley JN, Williams AE, Heffner TG.

Psychopharmacology (Berl). 1988;95(3):329-32.

PMID:
2901126
48.

1,3-Dialkyl-4-(iminoarylmethyl)-1H-pyrazol-5-ols. A series of novel potential antipsychotic agents.

Wise LD, Butler DE, DeWald HA, Lustgarten DM, Pattison IC, Schweiss DN, Coughenour LL, Downs DA, Heffner TG, Pugsley TA.

J Med Chem. 1987 Oct;30(10):1807-12.

PMID:
2888897
49.

N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.

Bridges AJ, Moos WH, Szotek DL, Trivedi BK, Bristol JA, Heffner TG, Bruns RF, Downs DA.

J Med Chem. 1987 Oct;30(10):1709-11. No abstract available.

PMID:
2888894
50.

(5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.

Wise LD, Butler DE, DeWald HA, Lustgarten D, Coughenour LL, Downs DA, Heffner TG, Pugsley TA.

J Med Chem. 1986 Sep;29(9):1628-37.

PMID:
2875184

Supplemental Content

Loading ...
Support Center